We are live on ! Find out more
BIOT

Biotech Acquisition Company Class A Ordinary Shares
BIOT

Delisted

BIOT was delisted on the 2nd of February, 2023.

Back to rankings

76 hedge funds and large institutions have $211M invested in Biotech Acquisition Company Class A Ordinary Shares in 2021 Q4 according to their latest regulatory filings, with 26 funds opening new positions, 9 increasing their positions, 10 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

225% more first-time investments, than exits

New positions opened: 26 | Existing positions closed: 8

44% more capital invested

Capital invested by funds: $146M → $211M (+$64.9M)

31% more funds holding

Funds holding: 58 → 76 (+18)

10% less repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 10

Holders
76
Holders Change
+18
Holders Change %
+31.03%
% of All Funds
1.17%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
26
Increased
9
Reduced
10
Closed
8
Calls
$96K
Puts
–
Net Calls
+$96K
Net Calls Change
-$2K

Top Buyers

Rank Fund Capital Flow
1
AC
Aristeia Capital
Connecticut
+$11.3M
2
CM
Cohanzick Management
New York
+$7.84M
3
RA
RiverPark Advisors
New York
+$7.84M
4
Marshall Wace
Marshall Wace
United Kingdom
+$5.9M
5
WCMNY
Westchester Capital Management (New York)
New York
+$5.11M

Top Sellers

Rank Fund Capital Flow
1
SRCM
Sage Rock Capital Management
New York
-$5.59M
2
ACM
Atalaya Capital Management
New York
-$5.4M
3
MP
Mangrove Partners
Connecticut
-$2.92M
4
CC
Centiva Capital
New York
-$2.42M
5
PP
Paloma Partners
Connecticut
-$498K
Name Holding Trade Value Shares
Change 		Change in
Stake
TRCT
76
Tower Research Capital (TRC)
New York
$2K +$1.91K +195 New
SRCM
77
Sage Rock Capital Management
New York
– -$5.59M -573,800 Closed
MP
78
Mangrove Partners
Connecticut
– -$2.92M -300,000 Closed
CC
79
Centiva Capital
New York
– -$2.42M -248,000 Closed
PP
80
Paloma Partners
Connecticut
– -$498K -51,100 Closed
TI
81
Telemetry Investments
New York
– -$390K -40,000 Closed
PI
82
PEAK6 Investments
Illinois
– -$137K -14,093 Closed
VCM
83
Vivaldi Capital Management
Illinois
– -$97K -10,000 Closed
S
84
SignatureFD
Georgia
– -$1K -72 Closed
1 2 3
4

BIOT Hedge Fund Activity: Q4 2021 in Review

76 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in Biotech Acquisition Company Class A Ordinary Shares (BIOT) for Q4 2021, worth a combined $211M — up 44% from $146M a quarter earlier.

Buyers outnumbered sellers: 26 funds opened new BIOT positions and 8 closed out — a net gain of 18 holders — while 9 added to existing stakes and 10 trimmed.

The largest buyer was Aristeia Capital, opening a new position worth an estimated $11.3M. The largest seller was Sage Rock Capital Management, exiting entirely with an estimated $5.59M sold.

  • 76 institutional investors held Biotech Acquisition Company Class A Ordinary Shares (BIOT) as of Q4 2021, up from 58 in Q3 2021.
  • Funds reported $211M of Biotech Acquisition Company Class A Ordinary Shares stock for Q4 2021, up 44% quarter-over-quarter.
  • 26 funds opened new Biotech Acquisition Company Class A Ordinary Shares positions in Q4 2021 and 8 closed out, a net change of +18 holders.
  • The largest Biotech Acquisition Company Class A Ordinary Shares buyer in Q4 2021 was Aristeia Capital, an estimated $11.3M added.
  • The largest Biotech Acquisition Company Class A Ordinary Shares seller in Q4 2021 was Sage Rock Capital Management, an estimated $5.59M sold.

Based on aggregated 13F filings for Q4 2021.